David Soergel Md

David Soergel, MD is the Global Head of Cardio Metabolic Development for Novartis, joining in 2017. Prior to this role, Dr. Soergel spent 9 years at biotechnology companies working in a variety of therapy areas, building high-performing development teams and conducting complex multi-stage adaptive trials. His most recent position was Senior Vice President of Clinical Development and Chief Medical Officer of Trevena, a Philadelphia-based biotechnology company developing biased ligands, medicines that selectively engage GPCRs. In that role, he was responsible for development of clinical strategy and design, execution and reporting of clinical trials in acute and chronic pain and acute heart failure. Prior to joining biotech, Dr. Soergel worked in early stage clinical development and translational medicine at GlaxoSmithKline, leading programs from the discovery organization into the clinic and through proof of concept. Dr. Soergel originally trained in pediatrics, pediatric cardiology and heart failure and transplant at Johns Hopkins Hospital and Children’s Hospital of Philadelphia. During his cardiology fellowship, Dr. Soergel completed an NIH sponsored NRSA post-doctoral fellowship at Johns Hopkins studying myofilament function in the laboratory of Anne Murphy, MD.

[Programming descriptions are generated by participants and do not necessarily reflect the opinions of SXSW.]